A Phase 2b Open-Label Single Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) .
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Tucidinostat (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors HUYA Bioscience International
- 10 Jan 2017 Status changed from not yet recruiting to recruiting.
- 22 Mar 2016 According to a company media release, HUYA has recently received orphan drug designation for HBI-8000 in Japan for peripheral T-cell lymphoma.
- 25 Mar 2015 New trial record